Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172191
Title: A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
Author: Sola Llopis, Susana de
Torre Fornell, Rafael de la
Sánchez Benavides, Gonzalo
Benejam, Bessy
Cuenca Royo, Aida
Hoyo, Laura del
Rodríguez, Joan
Catuara-Solarz, Silvina
Sanchez-Gutierrez, Judit
Dueñas Espín, Ivan
Hernandez, Gimena
Peña-Casanova, Jordi
Langohr, Klaus
Videla, Sebas
Blehaut, Henry
Farré Albaladejo, Magí
Dierssen, Mara
TESDAD Study Group
Keywords: Síndrome de Down
Assaigs clínics
Cognició
Down syndrome
Clinical trials
Cognition
Issue Date: 4-Jun-2015
Publisher: Frontiers Media
Abstract: The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fpsyg.2015.00708
It is part of: Frontiers in Psychology, 2015, vol. 6, p. 708
URI: http://hdl.handle.net/2445/172191
Related resource: https://doi.org/10.3389/fpsyg.2015.00708
ISSN: 1664-1078
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
699731.pdf1.04 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons